The Times Australia
PR Newswire

.

European Commission Approves mAbxience's Bevacizumab For The Treatment Of Certain Types Of Cancer

mAbxience, a global fully-fledged biotech company, with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals, is expanding patient access to biological treatments throughout Europe.

MADRID, March 31, 2021 /PRNewswire/ -- On 31 March 2021, the European Commission (EC) has approved mAbxience's MB02 biosimilar to Avastin® (Bevacizumab), in Europe.

MB02, to be commercialized as Alymsys® and Oyavas®, is highly similar to the reference medicinal product and data has shown a comparable quality, safety and efficacy to Avastin®. MB02 is intended for the treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

"We are currently witnessing a period of vital importance globally, with a key focus on the healthcare system and its sustainability," said Emmanuelle Lepine, General Manager at mAbxience.

"The launch of our Bevacizumab under the trademarks Alymsys® and Oyavas® in the European market will be a perfect example of how innovation and cutting-edge R&D technology can be applied to obtain a high quality, affordable medicine which, as well as providing alternatives for the healthcare system, will also improve patient access to costly treatments."

About mAbxience

mAbxience is a fully integrated global biopharmaceutical company specialising in the development, manufacture and commercialization of monoclonal antibodies, and forms part of the pharmaceutical group Insud Pharma. Founded in 2010, mAbxience operates three state of the art facilities, located in Spain and Argentina. mAbxience is working on several biopharmaceutical products spanning to different therapeutic areas. In 2014 mAbxience launched its first biosimilar, Rituximab (Product Code: RTXM83-MB01), which is now approved and marketed in a range of markets worldwide. Its second product, Bevacizumab (Product Code: BEVZ92-MB02), was first developed and launched in Latin America in 2016.

mAbxience is committed to the quality, safety and efficacy of its medicines. The mAbxience team is passionate about patient care and expanding access to its biopharmaceutical medicines all over the world. The Company's mission is to improve patient access to quality treatments for conditions that require costly medications and positively contributing to the sustainability of healthcare systems.

The Insud Pharma Group was founded by Dr. Hugo Sigman and Dr. Silvia Gold and has over 40 years' experience in the pharmaceutical sector and employs over 6,000 professionals worldwide.

Disclaimer

Some of the statements in this press release other than statements of historical fact, may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties, same as our business, as well as each product we develop and market, is subject to various risks and uncertainties beyond our control. Forward-looking statements represent the judgment of mAbxience's management as of the date of this release, and mAbxience disclaims any intent or obligation to update any forward-looking statements contained herein, which speak as of the date hereof.

Read more https://www.prnasia.com/story/archive/3325243_AE25243_0

Business Times

Agentforce for Financial Services: Merging AI and Human Expertise…

In this rapidly evolving world of financial services, deploying customer experiences that are personalized and intelligen...

Samsara Eco and lululemon announce 10 year partnership

lululemon and Samsara Eco Announce 10-Year Plan to Advance Recycled Material Portfolio Plan will see lululemon source a...

Barelli Bathrooms announces celebrity interior designer Kellie Ri…

Barelli Bathrooms, a leading name in contemporary bathroom accessories and design, is proud to announce its new national ...

The Times Features

Tricia Paoluccio designer to the stars

The Case for Nuturing Creativity in the Classroom, and in our Lives I am an actress and an artist who has had the privilege of sharing my work across many countries, touring my ...

Duke of Dural to Get Rooftop Bar as New Owners Invest in Venue Upgrade

The Duke of Dural, in Sydney’s north-west, is set for a major uplift under new ownership, following its acquisition by hospitality group Good Beer Company this week. Led by resp...

Prefab’s Second Life: Why Australia’s Backyard Boom Needs a Circular Makeover

The humble granny flat is being reimagined not just as a fix for housing shortages, but as a cornerstone of circular, factory-built architecture. But are our systems ready to s...

Melbourne’s Burglary Boom: Break-Ins Surge Nearly 25%

Victorian homeowners are being warned to act now, as rising break-ins and falling arrest rates paint a worrying picture for suburban safety. Melbourne residents are facing an ...

Exploring the Curriculum at a Modern Junior School in Melbourne

Key Highlights The curriculum at junior schools emphasises whole-person development, catering to children’s physical, emotional, and intellectual needs. It ensures early year...

Distressed by all the bad news? Here’s how to stay informed but still look after yourself

If you’re feeling like the news is particularly bad at the moment, you’re not alone. But many of us can’t look away – and don’t want to. Engaging with news can help us make ...